Arrowhead Pharmaceuticals, Inc.
Organic compositions to treat HSF1-related diseases
Last updated:
Abstract:
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
Status:
Grant
Type:
Utility
Filling date:
14 May 2019
Issue date:
17 Aug 2021